ベトナムの肺炎球菌ワクチン市場の評価：ワクチンタイプ・ワクチンプロパティ・投与経路・年齢層・エンドユーザー・流通チャネル・地域別の機会および予測 (2017-2031年)

ベトナムの肺炎球菌ワクチンの市場規模は、2023年の1億1万米ドルから、2024年から2031年の予測期間中は8.23%のCAGRで推移し、2031年には1億8,829万米ドルの規模に成長すると予測されています。

ベトナムの肺炎球菌ワクチン市場は、ワクチン接種プログラムに対する意識の高まり、肺炎球菌疾患の発生率の上昇、特に重症感染症にかかりやすい高齢者人口の増加など、複数の要因によって力強い成長を遂げています。さらに、政府や国際保健機関は予防接種プログラムを強化し、肺炎球菌疾患の負担を軽減するためのイニシアチブを実施する上で積極的な役割を果たしており、ベトナムの肺炎球菌ワクチン市場の拡大を後押ししています。

ベトナムの肺炎球菌ワクチン市場は、肺炎の発生率の上昇から大きな影響を受けています。肺炎は主に、小児、高齢者、免疫力の低下した人など、感染しやすい人々を襲います。罹患率の上昇により、現在では啓発キャンペーンが盛んに行われています。さらに、肺炎球菌疾患に対する包括的な治療法を提供するための製薬会社や研究機関の努力により、ベトナムの肺炎球菌ワクチン市場は目覚ましい進展と創造性を見せています。肺炎球菌ワクチン接種のアベイラビリティとアクセスのしやすさは、技術開発とヘルスケアインフラへの支出の増加により大幅に改善されました。

さらに、政府プログラムや世界の保健機関との提携がベトナムの肺炎球菌ワクチン市場の成長に大きな影響を与えています。積極的な予防接種プログラムと戦術的パートナーシップの牽引により、ワクチン接種率は上昇し、肺炎球菌感染症に対する一般市民の意識も高まっています。

肺炎の高い有病率：

ベトナムは小児肺炎の有病率が上位15カ国にランクインしています。この呼吸器疾患は、ベトナムの小児病院における入院の主な原因となっています。ベトナムでは、栄養不良、不十分な母乳育児、不十分な予防接種、低出生体重、室内汚染、過密な生活環境など、さまざまな危険因子が5歳未満の子供の重症肺炎の原因となっています。

技術の進歩が市場を牽引：

技術的進歩がベトナムの肺炎球菌ワクチン市場の急成長の原因となっています。肺炎球菌ワクチン接種は、初期には全細胞ベースの技術を用いて開発されました。これは、南アフリカの鉱山労働者を苦しめていた血清型1番の細菌を熱で殺したものを患者に接種するものでした。しかし、MacLeodらによる研究で、莢膜多糖体による免疫によってこの病気が予防されることが示され、その結果、純粋な莢膜多糖体がワクチン製剤に使用されるようになっています。現在使用されている肺炎球菌予防接種は、ヒトの疾病をもっとも頻繁に引き起こす少数の血清型に由来する純粋な莢膜多糖体です。現在、ほとんどのライセンシング機関は、莢膜多糖体を含む2種類のワクチンを承認しています。1つはPPSVで、PCVです。これらのワクチン製剤がベトナムの肺炎球菌ワクチン市場の成長に大きく貢献しています。

当レポートでは、ベトナムの肺炎球菌ワクチンの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 ベトナムの肺炎球菌ワクチン市場の展望

• 市場規模・予測
• ワクチンタイプ別
  • 生弱毒化ワクチン
  • 不活化ワクチン
  • サブユニットワクチン
  • 組み換えワクチン
• ワクチンプロパティ別
  • アジュバント
  • 非アジュバント
• 投与経路別
  • 筋肉内
  • 皮下
  • 皮内
  • その他
• 年齢別
  • 乳児
  • 小児
  • 成人
• エンドユーザー別
  • 病院
  • 専門クリニック
  • 在宅ケア
  • その他
• 流通チャネル別
  • 病院
  • 小売薬局
  • オンライン薬局
  • NGO
• 地域別
  • 北部
  • 南部
  • 中部
• 企業別市場シェア

第5章 市場マッピング

• ワクチンタイプ別
• ワクチンプロパティ別
• 投与経路別
• 年齢別
• エンドユーザー別
• 流通チャネル別
• 地域別

第6章 マクロ環境と産業構造

• 供給需要分析
• 輸入輸出分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第7章 市場力学

• 成長促進因子
• 成長阻害因子 (課題・制約)

第8章 規制枠組みとイノベーション

• 臨床試験
• 特許情勢
• 規制当局の承認
• イノベーション/新興技術

第9章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析（参入5社）
• 特許分析（該当する場合）

第10章 価格分析

第11章 ケーススタディ

第12章 主要企業の展望

• Pfizer Inc.
• Merck & Co., Inc.
• Walvax Biotechnology Co. Ltd.
• GlaxoSmithKline PLC.
• PnuVax Incorporated
• Novartis AG
• Serum Institute of Vietnam Pvt. Ltd.
• Panacea Biotec Limited
• Shenzhen Kangtai Biological Products Co., Ltd
• Sanofi Pasteur SA

第13章 戦略的提言

第14章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Vietnam Pneumococcal Vaccine Market, By Value, In USD Million, 2017-2031F
• Figure 2. Vietnam Pneumococcal Vaccine Market, By Volume, In Thousand Units, 2017-2031F
• Figure 3. Vietnam Pneumococcal Vaccine Market Share (%), By Type of Vaccine, 2017-2031F
• Figure 4. Vietnam Pneumococcal Vaccine Market Share (%), By Vaccine Property, 2017-2031F
• Figure 5. Vietnam Pneumococcal Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 6. Vietnam Pneumococcal Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 7. Vietnam Pneumococcal Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 8. Vietnam Pneumococcal Vaccine Market Share (%), By Distribution Channel, 2017-2031F
• Figure 9. Vietnam Pneumococcal Vaccine Market Share (%), By Region, 2017-2031F
• Figure 10. By Type of Vaccine Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 11. By Vaccine Property Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 12. By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 13. By Age Group Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 14. By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 15. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 16. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023

Vietnam pneumococcal vaccine market is projected to witness a CAGR of 8.23% during the forecast period 2024-2031, growing from USD 100.01 million in 2023 to USD 188.29 million in 2031. The Vietnam pneumococcal vaccine market is experiencing robust growth driven by multiple factors, such as an increased awareness of vaccination programs, a rise in pneumococcal disease incidences, and a growing elderly population that is particularly susceptible to severe infections. Additionally, governments and international health organizations are playing an active role in enhancing immunization programs and implementing initiatives to alleviate the burden of pneumococcal diseases, further bolstering the expansion of the Vietnam pneumococcal vaccine market.

The Vietnam pneumococcal vaccine market is significantly impacted by the rising incidence of pneumonia. Pneumonia primarily strikes susceptible populations, including children, the elderly, and those with weakened immune systems. There are now more awareness-raising campaigns because of the rise in instances. Moreover, due to the efforts of pharmaceutical companies and research organizations to provide comprehensive treatments against pneumococcal diseases, the Vietnam pneumococcal vaccine market has seen outstanding progress and creativity. Pneumococcal vaccination availability and accessibility have significantly improved because of technological developments and increased spending on healthcare infrastructure.

Additionally, government programs and alliances with global health organizations have had a big impact on the growth of the Vietnam pneumococcal vaccine market. As proactive immunization programs and tactical partnerships have gained traction, vaccine coverage has grown, and public awareness of pneumococcal illnesses has grown.

High Prevalence of Pneumonia

Vietnam ranks among the top 15 countries with the highest prevalence of child pneumonia. This respiratory condition is a major cause of hospital admissions in pediatric hospitals in Vietnam. Various risk factors contribute to severe pneumonia among children under the age of 5 in Vietnam, including malnutrition, inadequate breastfeeding practices, insufficient vaccinations, low birth weight, indoor pollution, and overcrowded living conditions. The impact of pneumonia on young children in Vietnam is well-documented; however, little is known about the prevalence of severe pneumonia and its risk factors in this age group. Therefore, the primary driver of the Vietnam pneumococcal vaccine market's expansion is the country's high rate of pneumonia cases.

Technological Advancements are Driving the Market

Technological advancements are responsible for the upsurge in the growth of the Vietnam pneumococcal vaccine market. Pneumococcal vaccinations were first developed utilizing whole-cell-based techniques. These entailed immunizing patients with heat-killed serotype 1 bacteria, which had afflicted South African miners. Nonetheless, studies by MacLeod et al. demonstrated that the sickness was prevented by immunization with capsular polysaccharides. Consequently, pure capsular polysaccharides were used in vaccine formulations. It is noteworthy that every pneumococcal serotype has biochemical and antigenic differences. It would be unfeasible to attain universal capsule-based immunization coverage against the hundreds of serotypes that are now in use. Rather, pure capsular polysaccharides from a small number of serotypes that cause human illness most frequently make up the pneumococcal vaccinations that are currently in use. Presently, most licensing agencies approve two types of vaccines containing capsular polysaccharides: one composed of 23 purified capsules (PPSV) and the other composed of 7, 10, or 13 purified capsules conjugated to a protein carrier (PCV). These vaccine formulations are significantly responsible for the growth of the Vietnam pneumococcal vaccine market.

The Demand for Pneumococcal Conjugate Vaccine is on the Rise

The extraordinary impact of the pneumococcal conjugate vaccination (PCV) is substantially responsible for the expansion of the Vietnam pneumococcal vaccine market. PCV is specially designed to boost the immune system's reaction to certain polysaccharides found on the bacteria's surface. These polysaccharides bind to carrier proteins through a process known as conjugation, which greatly improves the immune system's capacity to recognize and successfully fight the infection. Because of its novel architecture, PCV not only boosts immunity but also offers broader protection against a larger variety of pneumococcal serotypes. This transformative vaccine has emerged as a vital tool in reducing the burden of pneumococcal-related diseases and has played a pivotal role in safeguarding public health on a global scale. In 2021, a trial of pneumococcal vaccine schedules for PCV10 and PCV 13 was conducted in Ho Chi Minh City, Vietnam. The trial was sponsored by Murdoch Children's Research Institute, an Australian pediatric medical research institute located in Melbourne, Victoria.

Intramuscular Vaccines are in Great Demand

High demand for intramuscular vaccines is driving the Vietnam pneumococcal vaccine market. Intramuscular vaccinations are preferred due to their ability to elicit a strong immune response. Strong and long-lasting immune system activation is made possible by the muscle tissue's abundant blood supply and greater concentration of antigen-presenting cells. This ultimately results in a notable upsurge in the generation of protective antibodies and cultivates an improved immune memory, both of which are essential for sustained protection against pneumococcal infections. On the other hand, intradermal delivery entails injecting the vaccine into the skin's underlying layer. Although there is evidence to support the usefulness of this method in eliciting a robust and long-lasting immune response for pneumococcal immunization, it is not as well-supported as other vaccines.

Future Market Scenario (2024-2031F)

Vietnam pneumococcal vaccine market will also be influenced by the active role of healthcare organizations in enhancing immunization programs.

The increasing awareness regarding pneumonia disease will propel the growth of the Vietnam pneumococcal vaccine market in the future.

Several products by different companies are in the pipeline which are likely to be launched in coming years. Thus, the availability of new vaccine formulations will drive the growth of the Vietnam pneumococcal vaccine market.

The shift in population demographics toward the geriatric population will cause an increase in the overall number of people with diseases, such as Pneumonia, thereby propelling the market expansion.

Key Players Landscape and Outlook

Over the years, the Vietnam pneumococcal vaccine market has undergone significant changes, spurred by the urgent mission to combat pneumococcal diseases and safeguard public health. Recognizing the gravity of this health challenge, a multitude of pharmaceutical companies, research institutions, and governmental bodies have come to appreciate the importance of working together and consolidating their efforts. In May 2023, Pfizer (Vietnam) Limited Company and Vietnam Vaccine Joint Stock Company entered a memorandum of understanding (MoU) with the shared objective of comprehensive cooperation to safeguard public health, proactively combat diseases, and align with global advancements in healthcare, thereby positively impacting the well-being of the Vietnamese population. The primary focus of this joint project is to improve the proficiency of personnel in the development, implementation, and management of real-world data on vaccination, commonly known as "Real-World Evidence," in Vietnam. By doing so, the collaboration aims to gain valuable insights into vaccination patterns among the Vietnamese people, ensuring the safety and efficacy of vaccination practices.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Vietnam Pneumococcal Vaccine Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Type of Vaccine
  • 4.2.1. Live Attenuated Vaccines
  • 4.2.2. Inactivated Vaccines
  • 4.2.3. Subunit Vaccines
    • 4.2.3.1. Original Pathogen
    • 4.2.3.2. Polysaccharide Vaccine
    • 4.2.3.3. Conjugate Vaccine
    • 4.2.3.4. Protein-based Vaccine
  • 4.2.4. Recombinant Vaccine
• 4.3. By Vaccine Property
  • 4.3.1. Adjuvanted
  • 4.3.2. Non-adjuvanted
• 4.4. By Route of Administration
  • 4.4.1. Intramuscular
  • 4.4.2. Subcutaneous
  • 4.4.3. Intradermal
  • 4.4.4. Others
• 4.5. By Age group
  • 4.5.1. Infants
  • 4.5.2. Children
  • 4.5.3. Adults
• 4.6. By End-user
  • 4.6.1. Hospitals
  • 4.6.2. Specialty Clinics
  • 4.6.3. Homecare
  • 4.6.4. Others
• 4.7. By Distribution Channel
  • 4.7.1. Hospital
  • 4.7.2. Retail Pharmacy
  • 4.7.3. Online Pharmacy
  • 4.7.4. Non-Governmental Organizations
• 4.8. By Region
  • 4.8.1. Northern
  • 4.8.2. Southern
  • 4.8.3. Central
• 4.9. By Company Market Share (%), 2023

5. Market Mapping, 2023

• 5.1. By Type of Vaccine
• 5.2. By Vaccine Property
• 5.3. By Route of Administration
• 5.4. By Age group
• 5.5. By End-user
• 5.6. By Distribution channel
• 5.7. By Region

6. Macro Environment and Industry Structure

• 6.1. Supply Demand Analysis
• 6.2. Import Export Analysis
• 6.3. Value Chain Analysis
• 6.4. PESTEL Analysis
  • 6.4.1. Political Factors
  • 6.4.2. Economic System
  • 6.4.3. Social Implications
  • 6.4.4. Technological Advancements
  • 6.4.5. Environmental Impacts
  • 6.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 6.5. Porter's Five Forces Analysis
  • 6.5.1. Supplier Power
  • 6.5.2. Buyer Power
  • 6.5.3. Substitution Threat
  • 6.5.4. Threat from New Entrant
  • 6.5.5. Competitive Rivalry

7. Market Dynamics

• 7.1. Growth Drivers
• 7.2. Growth Inhibitors (Challenges and Restraints)

8. Regulatory Framework and Innovation

• 8.1. Clinical Trials
• 8.2. Patent Landscape
• 8.3. Regulatory Approvals
• 8.4. Innovations/Emerging Technologies

9. Key Players Landscape

• 9.1. Competition Matrix of Top Five Market Leaders
• 9.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 9.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 9.4. SWOT Analysis (For Five Market Players)
• 9.5. Patent Analysis (If Applicable)

10. Pricing Analysis

11. Case Studies

12. Key Players Outlook

• 12.1. Pfizer Inc.
  • 12.1.1. Company Details
  • 12.1.2. Key Management Personnel
  • 12.1.3. Products & Services
  • 12.1.4. Financials (As reported)
  • 12.1.5. Key Market Focus & Geographical Presence
  • 12.1.6. Recent Developments
• 12.2. Merck & Co., Inc.
• 12.3. Walvax Biotechnology Co. Ltd.
• 12.4. GlaxoSmithKline PLC.
• 12.5. PnuVax Incorporated
• 12.6. Novartis AG
• 12.7. Serum Institute of Vietnam Pvt. Ltd.
• 12.8. Panacea Biotec Limited
• 12.9. Shenzhen Kangtai Biological Products Co., Ltd
• 12.10. Sanofi Pasteur SA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

13. Strategic Recommendations

14. About Us & Disclaimer